A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma

Maryann Kaler; Amisha V Barochia; Nargues A Weir; Rosemarie A Cuento; Mario Stylianou; Mark J Roth; Armando C Filie; Ellen C Vaughey; Steven D Nathan; Stewart J Levine

doi:10.1016/j.jaci.2017.05.033

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma

J Allergy Clin Immunol. 2017 Dec;140(6):1716-1718. doi: 10.1016/j.jaci.2017.05.033. Epub 2017 Jun 15.

Authors

Affiliations

¹ Laboratory of Asthma and Lung Inflammation, Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
² Laboratory of Asthma and Lung Inflammation, Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md; Advanced Lung Disease and Lung Transplant Clinic, Inova Fairfax Hospital, Falls Church, Va.
³ Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.
⁴ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Md.
⁵ Northern Virginia Pulmonary and Critical Care Associates, Annandale, Va.
⁶ Advanced Lung Disease and Lung Transplant Clinic, Inova Fairfax Hospital, Falls Church, Va.
⁷ Laboratory of Asthma and Lung Inflammation, Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md. Electronic address: levines@nhlbi.nih.gov.

Abstract

The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe asthma.

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Intramural

MeSH terms

Adult
Asthma / drug therapy*
Cross-Over Studies
Double-Blind Method
Female
Humans
Hypoglycemic Agents / therapeutic use*
Male
Middle Aged
Pioglitazone / therapeutic use*

Substances

Hypoglycemic Agents
Pioglitazone

Abstract

Publication types

MeSH terms

Substances

Grants and funding